Summary
The provided claims are not grounded in the supplied FDA label excerpts and include assertions about current marketing/availability and cross-country listing/stocking that are not addressed by the provided sections; therefore they cannot be confirmed as on-label and may be unsupported.
Category Scores
Accurate Statements
Unsupported Statements
Pradaxa (dabigatran etexilate) is still marketed and available in at least some countries, including the United States.
The provided prescribing information excerpts do not address marketing status, product availability, or country-by-country distribution.
Pradaxa remains listed as an active prescription product.
No provided label section addresses whether Pradaxa is listed as an active prescription product (e.g., regulatory listing databases).
Pradaxa has not been broadly withdrawn from the market.
No provided label content addresses whether the product has been withdrawn from the market.
Pradaxa use has continued alongside other anticoagulants, including other direct oral anticoagulants.
The provided label excerpts (5.1, 5.3, 2.8, contraindications, 5.2) do not discuss comparative concurrent use patterns at the market/public-health level.
Drug availability depends on local approvals and commercial decisions.
The provided label excerpts do not discuss availability determinants such as local approvals or commercial decisions.
Even if Pradaxa is marketed in one country, it may not be stocked or prescribed in another country.
No provided label excerpts address stocking/prescribing practices by country.
Contradictions
Important Omissions
Any label-supported content relevant to the supplied prescribing information excerpts (e.g., boxed warnings about premature discontinuation and spinal/epidural hematoma, bleeding risk, contraindications, or peri-procedural discontinuation timing).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The claims evaluated are about marketing/availability rather than dosing or safety actions. However, they are unsupported by the provided label excerpts, so accuracy risk exists.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
The claims concern marketing/listing/availability across countries, which are not addressed in the supplied FDA label excerpts; thus they are unsupported for label alignment.
Suggested Improvement
Limit evaluation to label content provided (e.g., boxed warnings in Sections 5.1 and 5.3, contraindications in Section 4, and peri-procedural discontinuation timing in Section 2.8). Remove or separately substantiate marketing/availability statements using sources other than the provided prescribing information.